Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Drug Topics Community Pharmacists' Report

Drug Topics
Community
Pharmacists' Report

DrugTopics.com

January 31, 2012

REIMBURSEMENTS

Retail groups object to proposed federal limits on generic reimbursement

Two key retail pharmacy groups, the National Association of Chain Drug Stores and the National Community Pharmacists Association, have renewed their opposition to proposed federal upper limits for generic drug reimbursement under Medicaid. » More

CONTINUING EDUCATION

Cardiometabolic disease: The pharmacist’s tools for managing dyslipidemia and hypertension

Also known as syndrome X or metabolic syndrome, this condition can lead to diabetes, hypertension, and cardiovascular disease. For patients, pharmacists are an ideal source of information and support. Earn up to 2 CPE credits. » Click here to login and take the exams.

CLINICAL NEWS

Review raises questions about why government stockpiling zanamivir, oseltamivir

Zanamivir and oseltamivir (Tamiflu, Roche) can help prevent and treat the symptoms of influenza, but there is not enough information to evaluate the drugs’ safety and efficacy for preventing the spread of flu or pneumonia, according to a new review published online January 18. » More

Survey

Do you agree that pharmacists should have the authority to prescribe medications?

a) Yes
b) No

Respond here and see what your colleagues think too.

Want to see the results of our last survey about President Obama’s executive order concerning prescription drug shortages? Click here.

FDA ACTIONS

FDA approves vismodegib for treating basal cell skin cancer

FDA has approved vismodegib (Erivedge, Curtis and Genentech, a member of the Roche Group) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer. » More

FDA approves first once-weekly treatment for type 2 diabetes

FDA has approved exenatide extended-release for injectable suspension (Bydureon, Amylin and Alkermes) — the first once-weekly treatment for type 2 diabetes. » More

FDA approves axitinib to treat renal cell carcinoma

FDA approved axitinib (Inlyta, Pfizer) to treat patients with an advanced kidney cancer called renal cell carcinoma who have not responded to another drug for this type of cancer. » More

CHAINS AND BUSINESS

Big moves by Walgreens: Drops PSC price, acquires Kmart files in 16 states

Walgreens has taken 2 major steps to grow the customer base of its pharmacies since ending its relationship with pharmacy benefits manager Express Scripts on January 1.
» More

TECHNOLOGY

Personal device for testing lung functions approved by FDA

The Spiro PD has been cleared to market by FDA for the use by a patient to test lung function in children, adolescents, and adults, the product’s developer, PMD Healthcare, announced. » More

ScriptPro pharmacy management software program judged Best in KLAS

ScriptPro’s Central Pharmacy Management System won a 2011 Best in KLAS award for Software Solutions (pharmacy, outpatient, retail), the 2 companies announced. » More

 
 
Twitter  

Follow us on Twitter

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

DT Blog

JP at Large

View from the Zoo

Viewpoints

Regulatory & Legal

 

Meetings & Events

Digital Edition

View current edition

Cover
 
Powered by Modern Medicine Advanstar Medical Communications Group

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.